ClinicalTrials.gov
public full text
Public Domain
Cohort Study of Patients With HER2-negative MBC and BRCA 1/2 Pathogenic Mutation
The purpose of this study is to investigate the prevalence germline pathogenic BRCA1/2 mutation in a large group of potential candidate of PARP inhibitors, among the unselected patients with HER2-negative unresectable locally advanced or metastatic breast cancer.
Conceptio Open Archive
Analyze & explore related research in Conceptio
Connect this record directly into your research workflow or AI agent. Explore citations across open repositories, query full text, and export structured proof bundles.
This document is indexed with metadata only: full text is not available in the archive for this record. Open the official source ↗
Related documents
- Factors influencing oncologists’ decisions for germline BRCA testing and adjuvant therapy selection in HER2-negative early breast cancer.#988621
- iPSC-derived breast cancer models: advancing the study of BRCA1-driven tumorigenesis.#138435
- Real-world effectiveness of PARP inhibitors after CDK4/6 inhibitor therapy in BRCA-mutated HR-positive/HER2-negative advanced breast cancer#222651
- Germline BRCA1/2 Mutations in a Large Clinic-Based Cohort of Patients with Metastatic Breast Cancer in France#374486
- Natural menopause, menarche and breast cancer risk in BRCA1 and BRCA2 pathogenic variant carriers: a Mendelian randomization analysis#147712
Record · ID 1128233
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Bring this data into your agent: Connect via MCP or API · 20 free credits to start · no card required
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive